SCHEMBL7499532

SCHEMBL7499532

CC(O)CCCCCCC(Cl)(Cl)Cl

nearest known ligand 0.36

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
ACACB O00763 1/20 0.36
ACACA Q13085 1/20 0.36
TRPV1 Q8NER1 1/20 0.36
TRPA1 O75762 1/20 0.36
ALDH1A1 P00352 2/20 0.34
MAPT P10636 1/20 0.34
TSHR P16473 1/20 0.33
SPHK1 Q9NYA1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27542726 0.80 LMNA (0.43) ACACBACACA
SCHEMBL11041100 0.79
SCHEMBL5014042 0.79 TRPV1 (0.50) TRPV1TRPA1ALDH1A1MAPTTSHR
SCHEMBL11384575 0.79 TRPV1 (0.50) TRPV1TRPA1ALDH1A1MAPTTSHR
SCHEMBL5136481 0.79 TRPV1 (0.50) TRPV1TRPA1ALDH1A1MAPTTSHR
SCHEMBL7757768 0.79 TRPV1 (0.50) TRPV1TRPA1ALDH1A1MAPTTSHR
SCHEMBL5136479 0.79 TRPV1 (0.50) TRPV1TRPA1ALDH1A1MAPTTSHR
SCHEMBL4443550 0.79 TRPV1 (0.50) TRPV1TRPA1ALDH1A1MAPTTSHR
SCHEMBL17002461 0.79 TRPV1 (0.50) TRPV1TRPA1ALDH1A1MAPTTSHR
SCHEMBL6285447 0.79 TRPV1 (0.50) TRPV1TRPA1ALDH1A1MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9770429-B2 4-methylsulfonyl-2-butenenitrile and its pharmaceutical use OLATEC THERAPEUTICS LLC (US) 2017-09-26 US disclosed
US-20170231944-A1 4-METHYLSULFONYL-2-BUTENENITRILE AND ITS PHARMACEUTICAL USE OLATEC THERAPEUTICS, INC. 2017-08-17 US disclosed
US-9522878-B2 4-methylsulfonyl-2-butenenitrile and its pharmaceutical use OLATEC THERAPEUTICS LLC (US) 2016-12-20 US disclosed
EP-3055286-A1 4-METHYLSULFONYL-2-BUTENENITRILE AND ITS PHARMACEUTICAL USE Olatec Therapeutics LLC (US) 2016-08-17 EP disclosed
US-20160207881-A1 4-METHYLSULFONYL-2-BUTENENITRILE AND ITS PHARMACEUTICAL USE OLATEC THERAPEUTICS, INC. 2016-07-21 US disclosed
CN-105683158-A 4-methylsulfonyl-2-butenenitrile and its pharmaceutical use 欧拉泰克治疗有限责任公司 2016-06-15 CN disclosed
WO-2015054008-A1 4-METHYLSULFONYL-2-BUTENENITRILE AND ITS PHARMACEUTICAL USE OLATEC INDUSTRIES LLC (US) 2015-04-16 WO disclosed
EP-0757681-B1 CONDENSED HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE AS GnRH ANTAGONISTS TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2002-09-18 EP disclosed
US-5834463-A CONTROLLING FERTILITY, MENSTRUAL CYCLES TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-11-10 US disclosed
EP-0757681-A1 CONDENSED HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE AS GnRH ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 1997-02-12 EP disclosed
WO-1995029900-A1 CONDENSED HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE AS GnRH ANTAGONISTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1995-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170231944-A1 4-METHYLSULFONYL-2-BUTENENITRILE AND ITS PHARMACEUTICAL USE NFKBIA, SUCLG1, CUTA ACACB 367/4885ACACA 513/4885TRPV1 598/4885
US-20160207881-A1 4-METHYLSULFONYL-2-BUTENENITRILE AND ITS PHARMACEUTICAL USE NFKBIA, SUCLG1, CUTA ACACB 367/4885ACACA 513/4885TRPV1 598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.